MedPath - Medical Intelligence Platform

A recent study identifies maternal and fetal vascular malperfusion as significant factors in retinopathy of prematurity (ROP) risk, enhancing current screening methods.
Maternal vascular malperfusion correlates with higher gestational age and lower birthweight, while fetal malperfusion is associated with lower birthweight and reduced mechanical ventilation duration.
Placental factors like distal villous hypoplasia, severe acute histologic chorioamnionitis, and funisitis are independently linked to ROP, offering new targets for early identification.
Evaluating placental risk factors shortly after birth may enable earlier identification of high-risk infants and personalized interventions to prevent ROP development.

Updated results from the Phase 1b RedirecTT-1 study show the combination of talquetamab and teclistamab yields high response rates in relapsed/refractory multiple myeloma patients.
The bispecific antibody combination demonstrates durable responses and a manageable safety profile, consistent with each agent's monotherapy profile.
Patients with extramedullary disease, often resistant to standard therapies, also showed meaningful overall response rates and duration of response with the combination.
The findings support further investigation of talquetamab-based combinations in multiple myeloma treatment, especially for those with limited options.

The PfSPZ vaccine showed significant efficacy against P. falciparum parasitemia in women anticipating pregnancy, offering a potential preconception immunization strategy.
In phase 2 trials, both doses of the PfSPZ vaccine demonstrated efficacy against parasitemia and clinical malaria at years 1 and 2 in women of childbearing age.
The vaccine was well-tolerated, with mild adverse events, and serious adverse events occurring at similar rates across study groups, including the placebo group.
Vaccine efficacy against post-conception P. falciparum parasitemia during first pregnancies was approximately 57% and 49% in the two dosage groups, respectively.

IDEAYA Biosciences reports interim Phase 2 data for darovasertib in neoadjuvant uveal melanoma (UM).
The FDA provided guidance on a registrational trial design based on a Type C meeting.
Darovasertib is a selective protein kinase C (PKC) inhibitor targeting primary and metastatic UM.
An investor webcast will present the Phase 2 clinical data and regulatory update.

BWC0977, a novel bacterial topoisomerase inhibitor, has demonstrated efficacy against multi-drug resistant pathogens, including strains resistant to fluoroquinolones and carbapenems.
The drug's unique mechanism of action targets a broad spectrum of bacteria, encompassing both Gram-positive and Gram-negative types, distinguishing it from traditional antibiotics.
Clinical trials have shown BWC0977 to be safe and well-tolerated in healthy volunteers, with ongoing development including an oral formulation to enhance patient accessibility.

The University of Hong Kong (HKU) is launching a recruitment round for its "Heartwise" study, aiming to enroll 3,000 patients.
The study seeks to improve the accuracy of the "P-Cardiac" tool, an AI-powered system for predicting cardiovascular disease risk.
"P-Cardiac" utilizes Asia's largest patient records database, encompassing 300,000 records from the Hospital Authority.
Researchers hope the improved tool will enhance cardiovascular disease risk assessment and personalize healthcare strategies.

A recent imaging study has elucidated the mechanisms behind BCG resistance in non-muscle invasive bladder cancer (NMIBC) by assessing gene and protein activity in tumor samples.
The study identified the upregulation of the immune checkpoint NKG2A in immune cells, suggesting a potential target for overcoming BCG resistance.
Findings from this research have directly led to the launch of the phase 2 ENHANCE trial (NCT06503614), which will test the combination of durvalumab and monalizumab.
The ENHANCE trial will enroll patients with BCG-unresponsive NMIBC, including carcinoma in situ and papillary tumors, with the goal of improving treatment outcomes.

The FDA has approved Shield, the first blood test for primary colorectal cancer screening, offering a less invasive option for average-risk adults.
Shield demonstrated high sensitivity in detecting existing colorectal cancers (83%) but lower sensitivity (13%) for precancerous polyps in a study of nearly 8,000 participants.
Experts emphasize the importance of follow-up colonoscopies after positive Shield test results to remove precancerous growths and prevent cancer deaths.
While Shield could increase screening rates, questions remain about its cost-effectiveness and long-term impact on reducing colorectal cancer incidence and mortality.

Pertussis cases in the U.S. have increased fivefold compared to last year, reaching the highest levels since 2014, indicating a return to pre-pandemic infection rates.
Current pertussis vaccines offer strong initial protection, but their effectiveness wanes after two to three years, contributing to the upward trend in infections despite high vaccination rates.
The FDA is considering the use of human challenge trials, where participants are intentionally infected, to accelerate the development and testing of more effective pertussis vaccines.
Experts are exploring if challenge trials can accurately measure vaccine efficacy, while acknowledging the need to refine these models to ensure they provide sufficient evidence for vaccine approval.

Moderna's mRNA vaccine demonstrates encouraging early results in a trial targeting advanced solid cancers, enhancing the immune system's ability to recognize and kill cancerous cells.
The vaccine represents a personalized approach, potentially offering an 'off-the-shelf' solution for various cancer types based on individual tumor profiles.
Early trial data suggests the vaccine's capability to stimulate immune responses against cancer cells, marking a significant step forward in cancer immunotherapy.
This development highlights the potential of mRNA technology beyond infectious diseases, paving the way for innovative cancer treatments.

AI-Powered Research

Premium Access

Clinical Trial News

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma

A Study of Real-Life Current Standards of Care in Participants With Relapsed and/or Refractory Multiple Myeloma

A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity

Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

Teclistamab or Talquetamab in Combination with Daratumumab for High-Risk Smoldering Myeloma (REVIVE Study)

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

Minimal Residual Disease-based Strategy with T-Cell Redirector After Treatment with Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Talquetamab in Combination With Iberdomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

A Study of Talquetamab for People with Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali

Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Malaria Transmission Season in Healthy African Adult Women of Childbearing Potential in Mali

A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of BWC0977 in Healthy Volunteers

A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer

Trending News

FDA Approves Streamlined Access for Bristol Myers Squibb CAR T Cell Therapies

UCB's Fenfluramine Achieves Positive Phase 3 Results in Ultra-Rare CDKL5 Deficiency Disorder

Vor Bio Secures Global Rights to Telitacicept in $4+ Billion Deal with RemeGen

ProFound Therapeutics Partners with Novartis in $775M Cardiovascular Drug Discovery Deal

Percheron Therapeutics Acquires Phase II-Ready Anti-VISTA Cancer Immunotherapy HMBD-002 in $290M Deal

Lipocine Initiates Phase 3 Trial for Oral Brexanolone in Postpartum Depression

FDA Approves Gamifant as First Treatment for Macrophage Activation Syndrome in Still's Disease

China Approves First Once-Daily Nebulized LAMA for COPD, Triggering $7.5M Milestone for Theravance

Bavarian Nordic Initiates First Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

Cellarity Initiates Phase 1 Trial of CLY-124, First-in-Class Oral Therapy for Sickle Cell Disease

Daily Pharma Insights